Uveal Melanoma is the most common primary intraocular malignancy in adulthood. Eye
preserving treatments can deliver equivalent life prognosis in the management of small and
medium sized uveal melanomas, as compared to enucleation. Plaque radiotherapy has emerged
as the most common eye-preserving treatment in the current management of uveal melanoma, but
is complicated by visual loss in approximately 70% of patients at 10 years follow-up.
Strategies for the prevention and early treatment of radiation retinopathy/maculopathy need
to be developed to improve visual outcomes following plaque treatment. Ranibizumab
(Lucentis) is the antigen binding fragment of a recombinant, humanized monoclonal antibody,
which inhibits the activity of vascular endothelial growth factor A, a mediator in the
development of choroidal neovascularization. Lucentis is commonly used in the eye for eye
conditions such as age related macular degeneration. This study will investigate the
possible benefit of Anti-VEGF therapy (Lucentis) in reducing the incidence of radiation
complications following plaque radiation for uveal melanoma.
- Age >18 years
- new diagnosis of choroidal melanoma
- scheduled for plaque radiotherapy at Wills Eye Health System
- Pre-existing retinal disorders (i.e. age-related macular degeneration, diabetic
maculopathy, retinal vascular occlusion, macular hole, surface wrinkling retinopathy)
- prior retinal detachment
- media opacities precluding accurate OCT imaging
- history of glaucoma
- age <18 years.